One of the newer options, Zepbound (tirzepatide), is a once-weekly injectable approved by the Food and Drug Administration for chronic weight management
Estos productos no estn destinados a diagnosticar, tratar, curar o prevenir ninguna enfermedad.
It should not be this difficult to get basic treatment information
Medical history, medication interactions, lifestyle readiness, and individual metabolic factors all inform whether GLP-1 therapy aligns with your health goals and clinical needs
Studies show that 50 to 80 percent of patients regain most or all of their weight within one year of discontinuing GLP-1 therapy
You're engaging with your treatment every day in small, meaningful ways that remind you why you started